Add this topic to your myFT Digest for news straight to your inbox
Disposal of stomach-drug business would cut Quebec-based company’s heavy debt load
Beware of platform companies that engage in little more than financial engineering
‘Eat or be eaten’ mindset to drive more deals as groups try to replace sales lost when patents expire
Internet TV, Valeant, Rifat sentencing, Ryanair U-turn and more
New $173 all-cash offer trumps Dublin group’s cash-and-stock terms
Drugmaker expected to offer more than $160 a share to fend off rival bid from Endo
Drugmaker moves ahead with fundraising after being outbid by Endo
Bid for US drugmaker tops lower offer from Valeant
Pharma group’s debt levels soar after it raises $22bn in new finance
Proposed cuts at the latest target amount to most of its budget
Deal marks return to big-ticket M&A after the defeat of Allergan bid last year
Takeover could mark drugmaker’s return to dealmaking
Allergan shouldn’t be afraid of due diligence
US equity markets rally after upbeat jobs report
Collapse of drugmaker’s Irish unit acquisition raises questions over inversions
Acquisition of gastrointestinal specialist would likely kill off Valeant’s offer for Botox maker
International Edition